ALVR-106

N/A

Report date: 2025/04/23 20:01:04

Base Information

Drug NameALVR-106
Drug Alias NameALVR-106
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsImmunologic cytotoxicity
TargetsNot applicable
Therapy Area/IndicationsMetapneumovirus infectionsRespiratory Syncytial Virus InfectionsParamyxoviridae Infections +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesBaylor College Of Medicine
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKalaris Therapeutics IncBaylor College Of Medicine
Active IndicationsN/A
Inactive IndicationsMetapneumovirus infectionsRespiratory Syncytial Virus InfectionsParamyxoviridae Infections +[5] 

Other Information

ATC CodeN/A
Related LinksN/A